 | This article relies excessively on references to primary sources. Please improve this article by adding secondary or tertiary sources. Find sources: "NicOx" – news · newspapers · books · scholar · JSTOR (June 2009) (Learn how and when to remove this message) |
 | |
| Company type | Société Anonyme |
|---|---|
| Traded as | Euronext: COX |
| Industry | research and development in biotechnology  |
| Founded | 1996 (1996) |
| Headquarters | Sophia Antipolis, France |
| Website | www |
Nicox S.A. is a French ophthalmology company developing treatments to maintain vision and improve ocular health. Nicox is headquartered in Sophia Antipolis, France, and its Chairman and CEO is Michele Garufi.
Nicox is listed on Euronext Paris (Compartment B: Mid-Caps; Ticker symbol: COX) and is part of the CAC Healthcare, CAC Pharma & Bio and Next 150 indexes. Its pipeline includes three programs in development, and it has two U.S. Food and Drug Administration (FDA) approved products.
Pipeline
Nicox's lead program in clinical development is NCX 470, a novel, second-generation nitric oxide-donating bimatoprost analog, for lowering intraocular pressure (IOP) in patients with glaucoma. NCX 470 is designed to release both bimatoprost, which is marketed under the brand name LUMIGAN, and nitric oxide following instillation into the eye. Bimatoprost is a prostaglandin analog, the most widely used class of drugs for IOP lowering in patients with open angle glaucoma and ocular hypertension.
The company is also developing NCX 4251, a proprietary formulation of fluticasone, for acute exacerbations of blepharitis. Nicox generates revenue from VYZULTA(R) in glaucoma and ZERVIATE(TM), or cetirizine ophthalmic solution, in allergic conjunctivitis. It has ongoing partnerships with Bausch & Lomb, Eyevance Pharmaceuticals and Ocumension Therapeutics.
Agreement with Ocumension
In 2019, Nicox and Ocumension Therapeutics signed an agreement to allow Ocumension the rights to develop and commercialize Zerviate, a cetirizine ophthalmic solution, for the Chinese and South East Asian markets. The deal would see Nicox eligible for up to $17.2 million, along with tiered royalties of between 5 and 9% of the net sales. In July 2021 the deal was amended and Ocumension paid $2 million to Nicox as an advance payment of future development and regulatory milestones.
References
- "COX: Nicox Stock Price Quote - EN Paris - Bloomberg". Bloomberg News.
- "Here's a French Biotech Investors May Not Care About Enough". Bloomberg.com. Retrieved 2018-08-08.
- "Michele Garufi, PDG de NicOx".
- "| live".
- "Nicox S.A. (NICXF) Stock Price Today, Quote & News | Seeking Alpha".
- Clinical trial number NCT03657797 for "Phase 2 Dose-Response Study Evaluating the Safety and Efficacy of NCX 470 vs Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension" at ClinicalTrials.gov
- Sambhara, Deepak; Aref, Ahmad A. (2014). "Glaucoma management: relative value and place in therapy of available drug treatments". Therapeutic Advances in Chronic Disease. 5 (1): 30–43. doi:10.1177/2040622313511286. PMC 3871276. PMID 24381726.
- "Prostaglandin analogs: The "gold standard" for glaucoma".
- Clinical trial number NCT03926026 for "Study Evaluating the Safety and Tolerability of NCX 4251 for the Treatment of Acute Exacerbations of Blepharitis" at ClinicalTrials.gov
- "NICOX: Nicox Announces ZERVIATE Launch by Partner Eyevance Pharmaceuticals in the United States". Bloomberg.com. 31 March 2020.
- "BRIEF-Nicox Updates Agreement with Ocumension Therapeutics on ZERVIATE". Reuters. 11 March 2020. Archived from the original on June 11, 2020.
- NICOX (2021-07-05). "Nicox to Receive $2 Million from Ocumension Therapeutics as Advance Milestone Payment under ZERVIATE® Agreement". GlobeNewswire News Room. Retrieved 2021-09-19.